EA201992186A1 - Антитела к par2 и пути их применения - Google Patents

Антитела к par2 и пути их применения

Info

Publication number
EA201992186A1
EA201992186A1 EA201992186A EA201992186A EA201992186A1 EA 201992186 A1 EA201992186 A1 EA 201992186A1 EA 201992186 A EA201992186 A EA 201992186A EA 201992186 A EA201992186 A EA 201992186A EA 201992186 A1 EA201992186 A1 EA 201992186A1
Authority
EA
Eurasian Patent Office
Prior art keywords
par2
antibodies
ways
application
antigen binding
Prior art date
Application number
EA201992186A
Other languages
English (en)
Inventor
Клер Добсон
Ричард Уилльямс
Иэн Гаррелл
Садхана Подичетти
Дэвид Фэирмен
Питер Торнтон
Филип Ньютон
Original Assignee
Медиммун Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун Лимитед filed Critical Медиммун Лимитед
Priority claimed from PCT/EP2018/056776 external-priority patent/WO2018167322A1/en
Publication of EA201992186A1 publication Critical patent/EA201992186A1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Rheumatology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

В настоящем изобретении предусмотрены антитела и антигенсвязывающие фрагменты, способные связывать PAR2. В некоторых вариантах осуществления антитела к PAR2 или их антигенсвязывающие фрагменты связывают PAR2 зависимым от pH образом. В настоящем изобретении дополнительно предусмотрены способы получения и применения антител и антигенсвязывающих фрагментов.
EA201992186A 2018-03-02 2018-03-16 Антитела к par2 и пути их применения EA201992186A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862637766P 2018-03-02 2018-03-02
PCT/EP2018/056776 WO2018167322A1 (en) 2017-03-16 2018-03-16 Anti-par2 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA201992186A1 true EA201992186A1 (ru) 2020-03-05

Family

ID=69942789

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992186A EA201992186A1 (ru) 2018-03-02 2018-03-16 Антитела к par2 и пути их применения

Country Status (1)

Country Link
EA (1) EA201992186A1 (ru)

Similar Documents

Publication Publication Date Title
EA202092847A1 (ru) Антитела к cd3 и их применение
CY1124384T1 (el) Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
BR112018067458A2 (pt) anticorpos para tigit
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
EA201692504A1 (ru) Триспецифичные связывающие молекулы и способы их применения
PH12019502087A1 (en) Anti-par2 antibodies and uses thereof
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
EA201390146A1 (ru) Антитела к матриксной металлопротеиназе 9
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
EA202090559A1 (ru) Мультиспецифические антитела, специфичные в отношении эпитопов вируса зика, и их применение
EA202091350A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
EA202190138A1 (ru) Анти-sirp-бета1 антитела и способы их использования
EA201992281A1 (ru) Связывающие молекулы, специфично связывающиеся с тау-белком
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
EA201990895A1 (ru) Антитела к о1 и варианты их применения
EA202190235A1 (ru) Антитела к cd33 и способы их применения
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA201791691A1 (ru) ОДНОДОМЕННЫЕ АНТИТЕЛА, НАПРАВЛЕННЫЕ НА CD1d
CL2023001064A1 (es) Proteína de unión al antígeno anti-steap1
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
ATE552266T1 (de) Modifizierte hiv-1-hüllproteine
MX2016011177A (es) Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos.